BioMelbourne Network Progressing BioIndustry

1st till 31st August - Small Business Festival Victoria. The festival will give small businesses the opportunity to learn practical new skills
and access new ideas to help boost their productivity and competitiveness. More

Victorian BioPortal

Looking for Something?

The Victorian BioPortal is the largest online search engine for biotechnology in Victorian with over 2,000 individual listings.

Start your search now

BioMelbourne Network

The Building Global Bridges program provides grants of between $100,000 & $500,000 to Victorian life science companies to develop partnerships with Massachusetts companies in late stage life sciences R&D projects. The program helps Victorian innovation to accelerate, access expertise, develop skills & better reach global markets and international investors. Applications close 17 September 2013.

Building Global Bridges

IDT Executes Binding Memorandum of Understanding with Mayne Pharma for Exclusive Distribution of Temozolomide in the US

29th July, 2014 - IDT has now secured US distribution for its generic Temozolomide product on favourable commercial terms. IDT  Australia  Limited  (ASX:IDT)  is  pleased  to  announce  that  it  has entered  into  a  binding  Memorandum  of  Understanding  (MOU)  with  Mayne  Pharma’s  US Products  division  to  distribute  IDT’s  generic  Temozolomide  product  in  the  United  States  of Am... read more…

Collaboration announced to advance malaria vaccine development

29th July, 2014 - Burnet Institute and ARTES Biotechnology have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI).The project will use exciting novel technology developed at Burnet Institute by Deputy Director, Associate Professor David Anderson and colleagues. ARTES holds the international patent rights and adapted the platf... read more…

Phosphagenics Opioid Patch Program Update

28th July, 2014 - • Next phase of the TPM®/Oxymorphone clinical development program has commenced• TPM®/Oxycodone Phase 2a trial to be conducted in Australia during Q4/2014• TPM®/Oxymorphone Phase 2 trial to be conducted in the United States in H1/2015 Australian drug delivery company, Phosphagenics Limited (“the Company”) (ASX: POH, OTCQX: PPGNY), provides the following update on its opioid t... read more…

Business Council of Australi (BCA) - Actions Needed to Build Australia’s Comparative Advantages

28th July, 2014 - Continuing Australia’s remarkable run of economic growth will require businesses and governments to take more deliberate and purposeful steps in response to global forces of change, Business Council of Australia President Catherine Livingstone said today. Ms Livingstone used her first major speech as BCA President to launch a landmark paper that recommends a radical rethink o... read more…

Dr who? Campaign to boost digital profile of Australia's female scientists

27th July, 2014 - Ever heard of Dora Lush? She was an Australian microbiologist working in the 1940s on developing a vaccine for a deadly disease known as scrub typhus. She accidentally pricked her finger with a contaminated needle. Three weeks later, she died from the very disease she was trying to tame. Hailed as a martyr for science by her contemporaries, she kept donating blood samples fro... read more…

Acrux Appoints New CEO

25th July, 2014 - Acrux (ASX: ACR) today announced the appointment of a new Chief Executive Officer and Managing Director, Mr. Michael Kotsanis. Michael is currently Chief Commercial Officer of Synthon Holding BV in the Netherlands. He has 25 years’ experience in the global pharmaceutical industry, beginning his career with Boehringer Ingelheim before moving to F. H. Faulding (which was acquire... read more…

ADMEDUS INCREASES STAKE IN IAN FRAZER’S VACCINES

24th July, 2014 -  Now owns over 66% of Admedus Vaccines  Positive interim Phase I HSV-2 data     Phase II HSV-2 programme scheduled to be initiated by end of this year Admedus (ASX: AHZ) today announced that it has increased its ownership in Admedus Vaccines, the platform vaccine development company led by Professor Ian Frazer. Over the last twelve months Admedus has increased its ho... read more…

Starpharma and Ansell Get approval for HIV-killing Condom

23rd July, 2014 - An Australian-developed virus-killing condom is a step closer to sale, following a key regulatory approval. Australian biotech firm Starpharma has developed an antiviral compound called VivaGel that laboratory tests have shown can inactivate up to 99.9 per cent of HIV, herpes and some other sexually transmitted viruses, reducing the risk of transmission. It has teamed up wit... read more…

dorsaVi to commence sale of ViMove in the US following FDA clearance

23rd July, 2014 - Wearable medical device company dorsaVi Limited (ASX: DVL) has today announced it will commence launch of ViMove in the United States following 510K clearance by the US Food and Drug Administration (FDA) for measuring, recording, and reporting on movement and muscle activity of the lower back / lumbar spine. “This is a terrific achievement for dorsaVi and opens up substantial... read more…

Phosphagenics' $19.3 million Capital Raising

11th July, 2014 - • Includes $3 million Share Purchase Plan• Upcoming opioid pain patch trials fully funded 11 July 2014, Melbourne:  Australian drug delivery company, Phosphagenics Limited (ASX:POH; OTCQX:PPGNY),has raised $19.3 million via a placement of $16.3 million to institutional and sophisticated investors in Europe, USA, Asia and Australia and $3 million from a share purchase plan (SP... read more…

Melbourne hosting the 20th International AIDS Conference (AIDS 2014)

9th July, 2014 - Participants from the biotechnology sector highlighted that Melbourne has the capability in this sector but it is challenging to promote it to potential clients who have not been to Melbourne and experienced the facilities. For international investors, seeing the facilities and the people who are part of a project is critical. Participants know that when investors visit Melbou... read more…

LBT INNOVATIONS PRESENTS RESULTS OF MOST EXTENSIVE STUDY OF LANDMARK APAS® TECHNOLOGY AT AUSTRALIAN CONFERENCE

7th July, 2014 - Australian  medical  technology  developer,  LBT  Innovations Limited  (ASX:  LBT),  yesterday presented the results of its most extensive study to date into the efficacy of its Automated Plate Assessment System (APAS®) – a breakthrough culture plate analysis system based on the company’s innovative intelligent image interpretation platform. The presentation by LBT’s Senior Mi... read more…

BioMelbourne Network Announces New CEO

4th July, 2014 - On behalf of the BioMelbourne Network board, I am delighted to announce the appointment of Dr Krystal Evans to the role of Chief Executive Officer. She will commence her full time duties in early August 2014 but will begin engagement with our members and secretariat during the month of July. Krystal is a well recognised advocate for science and technology in Australia, with a ... read more…

dorsaVi acquires Australian Workplace Compliance to drive OH&S market expansion

4th July, 2014 - Medical device company dorsaVi Limited (ASX: DVL) (“the Company”) has today announced the acquisition of Australian Workplace Compliance Pty Ltd to increase the Company’s service offering and client base in the occupational health and safety (OH&S) market. Australian Workplace Compliance was founded by Mark Heaysman and provides OH&S operational and procedural analysis, suppor... read more…

d3 Medicine LLC and Viroclinics Biosciences BV form Virology Drug Development Alliance

2nd July, 2014 - We are thrilled to announce today that we have formalised collaborations with Viroclinics Biosciences - a recognised global leader in diagnostic, preclinical and clinical operation services in the virology space. Please see the attached press release. Together we seek to provide biopharmaceutical customers with an integrated solution to accelerate the preclinical and clinical ... read more…

Australia Jumps to Fourth in Global Biotech Ranking

1st July, 2014 - Melbourne, Australia’s leading life sciences industry on display at 2014 BIO International Convention San Diego, CA - July 1, 2014 - More than 70 delegates from Melbourne, Australia attended the 2014 BIO International conference showcasing their strong life sciences cluster.  At this year’s convention, Scientific American Worldview announced its annual global rankings of the b... read more…

Dr John Dixon Hughes OAM Medal for Medical Research Innovation

26th June, 2014 - The National Foundation for Medical Research and Innovation (NFMRI) is pleased to offer the Dr John Dixon Hughes OAM Medal for Medical Research Innovation every two years to a researcher under the age of 45 for outstanding contribution towards the development and advancement of a biomedical innovation related to the nature, prevention, diagnosis, treatment and incidence of dis... read more…

Bionomics and Merck Enter New Research Collaboration

24th June - Agreement to fund development of compounds for cognitive impairment associated with Alzheimer’s disease and other conditions of the central nervous system.Bionomics Limited (ASX:BNO, ADR:BMICY) announces that it has entered into an exclusive Research Collaboration and License Agreement with Merck, known as MSD outside the United States and Canada, for its BNC375 research program tar... read more…

Wild Success In Time Of Challenge

23rd June - Wild Child cosmeceuticals is set to float on the Australian stock exchange, in the latest bid for a global reach by the WA company that started on a kitchen table. Founder Leanne Preston said a new state-of-the-art factory in Malaga - a milestone move that bucks the trend to go offshore - as well as a range of new markets and products are in line with the expansion strategy. But t... read more…

Phosphagenics to Strengthen Skincare Partnership with Prestige Cosmetics Brand Le Métier de Beauté

12th June - Australian drug delivery technology company, Phosphagenics Limited (ASX: POH, OTCQX: PPGNY), will continue its partnership for the use of its TPM® dermal delivery technology in Le Métier de Beauté (LMDB) skincare products after the sale of LMDB’s key assets in the United States. The sale to Maison de Beauté LLC was approved in late May after LMDB entered into a voluntary Chapter 11... read more…